Ticker Symbol: TOS/TSX FOR IMMEDIATE RELEASE
Shares Outstanding: 58,027,389
QUEBEC CITY, June 7, 2011 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in sterilization technology for medical
devices in healthcare settings, today announced that it has begun to
support 3M™ commercialization efforts by shipping new 3M™ Optreoz™
125-Z sterilizers for installation at customer locations.
"Months of collaboration with our channel partner are now showing
tangible results", said R.M. (Ric) Rumble, President and CEO of TSO3. "We are beginning to ship units from our backlog and have additional
shipments planned for next month and beyond. Our efforts are now in
direct support of our channel partner's phased introduction of the new
technology, as was previously outlined during our Annual General
Meeting of Shareholders (AGM)", Mr. Rumble concluded.
As part of the recent AGM held on May 11, 2011, information was shared
by TSO3 including examples of launch materials provided by 3M™ regarding their
approach to launching the 3M™ Optreoz™ 125-Z Sterilizer. This material
includes product positioning to customers and launch sequences in more
than a dozen countries, as well a communications strategy, examples of
print literature and E-tools. The webcast of this event and the
PowerPoint presentation will be archived for a period of 90 days and
are available at http://www.cnw.ca/en/webcast/viewEvent.cgi?eventID=3474900
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solution to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
SOURCE TSO3 INC.
For further information:
Source: TSO3 Inc.
Director, Corporate Communications